CDI Global
Person name

Wayne Weiner

CDI Global Member

Experience & Qualifications

Wayne Weiner is a senior industry advisor to CDI Global North America, with extensive experience in strategic planning and M&A advisory, with particular focus on the pharmaceutical services industry.

Wayne was most recently Vice President Corporate Development for Patheon, one the industry’s leading pharmaceutical contract manufacturing organizations. Prior to joining Patheon, Wayne was Vice President Strategy and Business Development at DSM Pharmaceutical Products (a subsidiary of Royal DSM N.V.). Wayne also has hands on experience in commercial development roles, serving as Vice President Sales and Marketing for DSM’s North American pharmaceutical chemical contract manufacturing business, and for Synthon Chiragenics Corporation, a leading supplier of specialized drug intermediates. Prior his activities in the pharma industry, Wayne began his career as a research chemist for Cytec Industries, where he developed proprietary chemicals for the semiconductor manufacturing industry. He rapidly advanced into various commercial roles serving the mining, coatings, and adhesives industries.

Wayne was an American Cancer Society post-doctoral fellow at Columbia University in New York. He earned his Ph.D. in chemistry from the University of California Berkeley, and B.Sc. degree in chemistry from the University of California, Los Angeles, which included studies at Georg-August University, Goettingen, Germany. Wayne is a member of BioNJ, the American Chemical Society, and the Société de Chimie Industrielle of New York. Wayne can be reached at or at + 1 201 739 9527

Connect with a CDI Expert. Request a Call Back.

News & Insights

Read more

November 22, 2023

Africa Merchant Capital, Lightstruck and Eos Capital partner on an open access fibre network in Namibia

Read more

November 20, 2023

Pourquoi avoir recours à un conseil en fusions et acquisitions comme CDI GLOBAL pour céder son entreprise ?

In memory of Jakub Frąckowiak
Navigating the New Landscape of Venture Capital Funding